Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-Lung-1 in extensive-stage small cell lung cancer
NL-OMON61136Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of obrixtamig in small cell lung cancer (SCLC), sponsored by Boehringer Ingelheim. Started Aug 2026; status: recruiting.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON61136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61136.